First Patient with Alzheimer’s Dosed in Bryostatin-1 Clinical Trial
source: pixabay.com

First Patient with Alzheimer’s Dosed in Bryostatin-1 Clinical Trial

  Last week, clinical stage biopharmaceutical company Neurotrope announced that the first patient was dosed in a Phase 2 clinical trial to test the safety, efficacy, and tolerability of bryostatin-1…

Continue Reading First Patient with Alzheimer’s Dosed in Bryostatin-1 Clinical Trial
Phase 3 Study Results Bring Hope for Children with Primary Hyperoxaluria Type 1  
source: pixabay.com

Phase 3 Study Results Bring Hope for Children with Primary Hyperoxaluria Type 1  

  According to a recent article in BioSpace, young children and infants who have been diagnosed with primary hyperoxaluria type 1 (PH1) are often faced with the use of gastrostomy…

Continue Reading Phase 3 Study Results Bring Hope for Children with Primary Hyperoxaluria Type 1  
The Glanzmann’s Research Foundation: Dedicated to Finding a Cure
source: pixabay.com

The Glanzmann’s Research Foundation: Dedicated to Finding a Cure

Patient Worthy has recently begun a partnership with the Glanzmann's Research Foundation, a nonprofit patient organization dedicated to spreading awareness about Glanzmann's thrombasthenia and finding a cure. We spoke with…

Continue Reading The Glanzmann’s Research Foundation: Dedicated to Finding a Cure
Experimental WHIM Syndrome Treatment Gets FDA Fast Track Designation
source: pixabay.com

Experimental WHIM Syndrome Treatment Gets FDA Fast Track Designation

According to a story from GlobeNewswire, the biopharmaceutical company X4 Pharmaceuticals, Inc. has just announced that the US Food and Drug Administration (FDA) has granted its investigational product candidate mavorixafor…

Continue Reading Experimental WHIM Syndrome Treatment Gets FDA Fast Track Designation
Close Menu